Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06072612 · ClinicalTrials.gov registry record · Phase 3
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
A Phase 3 study of Breast Cancer and Metastatic Breast Cancer, sponsored by BriaCell Therapeutics Corporation.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 404
- Enrollment target
- 20
- Study locations
NCT06072612 is a Phase 3 study of Breast Cancer and Metastatic Breast Cancer that is actively recruiting participants, run by BriaCell Therapeutics Corporation. The registered enrollment target is 404 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 2 states.
The verdict
NCT06072612, a Phase 3 study of Breast Cancer and Metastatic Breast Cancer, is actively recruiting participants, sponsored by BriaCell Therapeutics Corporation.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 404 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with no approved alternative therapies available.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Retifanlimab
- BIOLOGICAL SV-BR-1-GM
- DRUG Interferon infiltration of the inoculation site
- DRUG Treatment of Physician's Choice
Study Locations (20)
California
- Los Angeles cancer Network_Anaheim - Anaheim
- Comprehensive Blood and Cancer Center - Bakersfield
- Cedars-Sinai Cancer Beverly Hills - Beverly Hills
- Los Angeles Cancer Network_Corona - Corona
- Los Angeles cancer Network_Fountain Vallley - Fountain Valley
- Los Angeles Cancer Network_Glendale - Glendale
- Hoag Hospital Center - Irvine
- Hoag Hospital Irvine - Irvine
- Los Angeles Cancer Network - Los Angeles
- Cedars-Sinai Cancer at Cedars-Sinai Medical Facility - Los Angeles
- Los Angeles Cancer Network_Century City - Los Angeles
- UCLA-Hematology/Oncology Medical Plaza - Los Angeles
- UCLA-Hematology/Oncology_LA 2 - Los Angeles
- UCLA-Hematology/Oncology_LA - Los Angeles
- Los Angeles Cancer Network_Pasadena - Pasadena
- Los Angeles cancer Network_Riverside - Riverside
- UC San Diego - San Diego
- St. John's Cancer Center - Santa Monica
Arizona
- Mayo Clinic-Comprehensive Cancer Center-Breast Clinic - Phoenix
- University of Arizona-Cancer Center - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 404 participants |
| Start Date | 2023-12-05 |
| Est. Completion | 2028-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06072612
The ClinicalTrials.gov registry entry for NCT06072612 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 404 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (86% lower). The listed sponsor is BriaCell Therapeutics Corporation, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT06072612 reports 20 study locations spanning 2 distinct geographic areas - top geographies include California, Arizona.
Frequently Asked Questions
What is clinical trial NCT06072612 about?
NCT06072612 is a clinical study titled "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.". This is a multicenter randomized, open label study to evaluate overall survival with the Bria-IMT regimen in combination with Checkpoint Inhibitor \[Retifanlimab\], versus Treatment of Patients'/Physicians' Choice (TPC) in advanced metastatic or locally recurrent breast cancer (aMBC) patients with n...
What is the current status of trial NCT06072612?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 404 participants. The study started on 2023-12-05. Estimated completion is 2028-06.
What conditions does trial NCT06072612 study?
This clinical trial studies the following conditions: Breast Cancer, Metastatic Breast Cancer, Breast Neoplasm, Breast Cancer Metastatic, End Stage Cancer.
What interventions are being tested in trial NCT06072612?
The interventions under investigation include: Cyclophosphamide (DRUG), Retifanlimab (DRUG), SV-BR-1-GM (BIOLOGICAL), Interferon infiltration of the inoculation site (DRUG), Treatment of Physician's Choice (DRUG).
Who is sponsoring clinical trial NCT06072612?
This trial is sponsored by BriaCell Therapeutics Corporation, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06072612 being conducted?
This trial has 20 study locations across Arizona, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
RECRUITING · Phase 3
-
Intensity Modulated Radiotherapy (IMRT) vs. 3D-conformal Accelerated Partial Breast Irradiation (APBI) for Early Stage Breast Cancer After Lumpectomy
RECRUITING · Phase 3
-
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
RECRUITING · Phase 3
-
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RECRUITING · Phase 3
-
A Study of a Comprehensive Prevention Program to Reduce Lymphedema After Axillary Lymph Node Dissection in People With Breast Cancer
RECRUITING · Phase 3
-
Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease
RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.